Clinical trials: High-Risk Cancer, open to volunteers
High Risk of Recurrence
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these…
- Trial name
- NCT06327269
- Testing
- Lenvatinib 10 mg
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Anal Intraepithelial Neoplasia 2, Anal Intraepithelial Neoplasia 1
Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
Human papillomavirus (HPV) infection has been implicated as a necessary cause for the development of the majority of anogenital neoplasms which represent approximately 95% of anal tumors.
- Conditions
- Anal Intraepithelial Neoplasia 2, Anal Intraepithelial Neoplasia 1, Anal Cancer, High-Risk Cancer
- Trial name
- NCT06327568
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- European Institute of Oncology
Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids…
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site, High-risk Human Papillomavirus Infection, Liquid Biopsy
- Trial name
- NCT05918510
- Testing
- Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
- Where
- Italy
- Volunteers
- 142 people
- Sponsor
- Regina Elena Cancer Institute
Liver Transplant; Complications, Hepatocarcinoma
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety…
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Trial name
- NCT06041490
- Testing
- multi-kinase inhibitors in combination with bevacizumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cancer, Healthy
Collection and Distribution of Biospecimens for Novel Research Uses
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with…
- Conditions
- Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
- Trial name
- NCT03848962
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Neoadjuvant Therapy, High Risk Prostate Cancer
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
- Conditions
- Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
- Trial name
- NCT05406999
- Testing
- ADT, Abiraterone Acetate, Prednisolone tablets
- Where
- China
- Volunteers
- 900 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
High-risk Prostate Cancer, Prostate Cancer
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+ valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in…
- Trial name
- NCT03541928
- Testing
- HSV-Tk, Valacyclovir, Bicalutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Methodist Hospital Research Institute
High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure
Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
PURPOSE: This study is being conducted to test the safety of the study drug Pembrolizumab, also known as MK-3475, at different dose levels in combination with the current therapy, (BCG), for superficial upper urinary tract…
- Conditions
- High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
- Trial name
- NCT03345134
- Testing
- MK-3475 and BCG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Shaheen Alanee